Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on developing genetic medicines for rare and prevalent diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. Geoff McDonough, M.D., the company's president and CEO, will engage in a fireside chat on Thursday, September 19, 2024, at 10:20 a.m. ET in New York.
Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. For those unable to attend the live event, a replay will be available on the same platform for 30 days following the conference.
Generation Bio Co. (Nasdaq: GBIO), una compagnia biotecnologica focalizzata sullo sviluppo di medicinali genetici per malattie rare e diffuse, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor 2024. Geoff McDonough, M.D., il presidente e CEO dell'azienda, parteciperà a una chat informale giovedì, 19 settembre 2024, alle 10:20 a.m. ET a New York.
Investitori e parti interessate possono accedere a una webcast in diretta della presentazione attraverso la sezione investitori del sito web di Generation Bio all'indirizzo investors.generationbio.com. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione sulla stessa piattaforma per 30 giorni dopo la conferenza.
Generation Bio Co. (Nasdaq: GBIO), una empresa biotecnológica centrada en el desarrollo de medicamentos genéticos para enfermedades raras y prevalentes, ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. Geoff McDonough, M.D., el presidente y CEO de la compañía, participará en una charla informal el jueves 19 de septiembre de 2024, a las 10:20 a.m. ET en Nueva York.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de inversores del sitio web de Generation Bio en investors.generationbio.com. Para aquellos que no puedan asistir al evento en vivo, se dispondrá de una retransmisión en la misma plataforma durante 30 días después de la conferencia.
Generation Bio Co. (Nasdaq: GBIO)는 희귀 및 흔한 질병을 위한 유전 치료제 개발에 집중하는 생명공학 회사로, 2024 칸토 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Geoff McDonough, M.D.는 회사의 회장 및 CEO로서 2024년 9월 19일 목요일 오전 10시 20분 ET에 뉴욕에서 파이어사이드 채팅에 참여할 예정입니다.
투자자 및 관심 있는 분들은 Generation Bio 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 통해 발표를 시청할 수 있습니다. 생중계에 참석하지 못한 분들을 위해, 컨퍼런스 후 30일 동안 동일 플랫폼에서 재생이 가능합니다.
Generation Bio Co. (Nasdaq: GBIO), une entreprise de biotechnologie axée sur le développement de médecines génétiques pour les maladies rares et répandues, a annoncé sa participation à la Conférence Mondiale sur la Santé Cantor 2024. Geoff McDonough, M.D., le président et PDG de l’entreprise, participera à un échange informel le jeudi 19 septembre 2024 à 10h20 ET à New York.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site Web de Generation Bio à investors.generationbio.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion sera disponible sur la même plateforme pendant 30 jours après la conférence.
Generation Bio Co. (Nasdaq: GBIO), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von genetischen Arzneimitteln für seltene und weit verbreitete Krankheiten konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Geoff McDonough, M.D., der Präsident und CEO des Unternehmens, wird am Donnerstag, den 19. September 2024, um 10:20 Uhr ET in New York an einem Feuerplatzgespräch teilnehmen.
Investoren und Interessierte können über den Investorenbereich der Website von Generation Bio auf die Live-Webcast der Präsentation zugreifen unter investors.generationbio.com. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, steht auf derselben Plattform bis zu 30 Tagen nach der Konferenz eine Wiedergabe zur Verfügung.
- None.
- None.
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the 2024 Cantor Global Healthcare Conference?
Who will represent Generation Bio (GBIO) at the 2024 Cantor Global Healthcare Conference?
How can I watch Generation Bio's (GBIO) presentation at the 2024 Cantor Global Healthcare Conference?
For how long will the replay of Generation Bio's (GBIO) presentation be available?
What is the focus of Generation Bio's (GBIO) research and development?
